BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36920356)

  • 1. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing.
    Kashani-Sabet M; Leachman SA; Stein JA; Arbiser JL; Berry EG; Celebi JT; Curiel-Lewandrowski C; Ferris LK; Grant-Kels JM; Grossman D; Kulkarni RP; Marchetti MA; Nelson KC; Polsky D; Seiverling EV; Swetter SM; Tsao H; Verdieck-Devlaeminck A; Wei ML; Bar A; Bartlett EK; Bolognia JL; Bowles TL; Cha KB; Chu EY; Hartman RI; Hawryluk EB; Jampel RM; Karapetyan L; Kheterpal M; Lawson DH; Leming PD; Liebman TN; Ming ME; Sahni D; Savory SA; Shaikh SS; Sober AJ; Sondak VK; Spaccarelli N; Usatine RP; Venna S; Kirkwood JM
    JAMA Dermatol; 2023 May; 159(5):545-553. PubMed ID: 36920356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit.
    Grossman D; Okwundu N; Bartlett EK; Marchetti MA; Othus M; Coit DG; Hartman RI; Leachman SA; Berry EG; Korde L; Lee SJ; Bar-Eli M; Berwick M; Bowles T; Buchbinder EI; Burton EM; Chu EY; Curiel-Lewandrowski C; Curtis JA; Daud A; Deacon DC; Ferris LK; Gershenwald JE; Grossmann KF; Hu-Lieskovan S; Hyngstrom J; Jeter JM; Judson-Torres RL; Kendra KL; Kim CC; Kirkwood JM; Lawson DH; Leming PD; Long GV; Marghoob AA; Mehnert JM; Ming ME; Nelson KC; Polsky D; Scolyer RA; Smith EA; Sondak VK; Stark MS; Stein JA; Thompson JA; Thompson JF; Venna SS; Wei ML; Swetter SM
    JAMA Dermatol; 2020 Sep; 156(9):1004-1011. PubMed ID: 32725204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management Decisions Made by Physician Assistants and Nurse Practitioners in Cutaneous Malignant Melanoma Patients: Impact of a 31-Gene Expression Profile Test.
    Mirsky R; Prado G; Svoboda R; Glazer A; Rigel D
    J Drugs Dermatol; 2018 Nov; 17(11):1220-1223. PubMed ID: 30500144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
    Serban ED; Farnetani F; Pellacani G; Constantin MM
    Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31-gene expression profile test.
    Ahmed K; Siegel JJ; Morgan-Linnell SK; LiPira K
    Cancer Med; 2023 Jan; 12(2):2008-2015. PubMed ID: 35915969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of a 31-Gene Expression Profile Into Clinical Decision-Making in the Treatment of Cutaneous Melanoma.
    Scott AM; Dale PS; Conforti A; Gibbs JN
    Am Surg; 2020 Nov; 86(11):1561-1564. PubMed ID: 32755379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.
    Farberg AS; Marson JW; Glazer A; Litchman GH; Svoboda R; Winkelmann RR; Brownstone N; Rigel DS;
    Dermatol Ther (Heidelb); 2022 Apr; 12(4):807-823. PubMed ID: 35353350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary.
    Johansson I; Tempel D; Dwarkasing JT; Rentroia-Pacheco B; Mattsson J; Ny L; Olofsson Bagge R
    Eur J Surg Oncol; 2022 Feb; 48(2):320-325. PubMed ID: 34794843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2023 Dec; 22(12):7691. PubMed ID: 38051842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating a Prognostic Gene Expression Profile Test into the Management of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel Report.
    Zakria D; Brownstone N; Berman B; Ceilley R; Cronin TA; Del Rosso JQ; Ferris LK; Goldenberg G; Siegel D
    J Drugs Dermatol; 2024 Feb; 23(2):54-60. PubMed ID: 38306124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Affecting Dermatologists' Use of a 31-Gene Expression Profiling Test as an Adjunct for Predicting Metastatic Risk in Cutaneous Melanoma.
    Svoboda RM; Glazer AM; Farberg AS; Rigel DS
    J Drugs Dermatol; 2018 May; 17(5):544-547. PubMed ID: 29742186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Gene Expression Profiling on Decision-Making in Clinically Node Negative Melanoma Patients after Surgical Staging.
    Schuitevoerder D; Heath M; Cook RW; Covington KR; Fortino J; Leachman S; Vetto JT
    J Drugs Dermatol; 2018 Feb; 17(2):196-199. PubMed ID: 29462228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis.
    Marchetti MA; Coit DG; Dusza SW; Yu A; McLean L; Hu Y; Nanda JK; Matsoukas K; Mancebo SE; Bartlett EK
    JAMA Dermatol; 2020 Sep; 156(9):953-962. PubMed ID: 32745161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expanded evidence that the 31-gene expression profile test provides clinical utility for melanoma management in a multicenter study.
    Dillon LD; McPhee M; Davidson RS; Quick AP; Martin B; Covington KR; Zolochevska O; Cook RW; Vetto JT; Jarell AD; Fleming MD
    Curr Med Res Opin; 2022 Aug; 38(8):1267-1274. PubMed ID: 35081854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma: How and when to consider clinical diagnostic technologies.
    Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
    J Am Acad Dermatol; 2022 Mar; 86(3):503-512. PubMed ID: 34915058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma.
    Mulder EEAP; Dwarkasing JT; Tempel D; van der Spek A; Bosman L; Verver D; Mooyaart AL; van der Veldt AAM; Verhoef C; Nijsten TEC; Grunhagen DJ; Hollestein LM
    Br J Dermatol; 2021 May; 184(5):944-951. PubMed ID: 32844403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dermoscopic features associated with 3-GEP PLA: LINC00518, PRAME, and TERT expression in suspicious pigmented lesions.
    Ludzik J; Becker AL; Latour E; Lee C; Witkowski A
    Skin Res Technol; 2023 Apr; 29(4):e13323. PubMed ID: 37083005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 31-gene expression profile stratifies recurrence and metastasis risk in patients with cutaneous melanoma.
    Jarell A; Skenderis B; Dillon LD; Dillon K; Martin B; Quick AP; Siegel JJ; Rackley BB; Cook RW
    Future Oncol; 2021 Dec; 17(36):5023-5031. PubMed ID: 34587770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dark pigmented lesions: Diagnostic accuracy of dermoscopy and reflectance confocal microscopy in a tertiary referral center for skin cancer diagnosis.
    Longo C; Mazzeo M; Raucci M; Cornacchia L; Lai M; Bianchi L; Peris K; Pampena R; Pellacani G
    J Am Acad Dermatol; 2021 Jun; 84(6):1568-1574. PubMed ID: 32730850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts.
    Fastner S; Shen N; Hartman RI; Chu EY; Kim CC; Kirkwood JM; Grossman D
    Cancer Med; 2023 Dec; 12(24):22103-22108. PubMed ID: 38098216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.